The new drug, doterral, will be administered in the first month of 2019 and is expected to help stop the growth of skin cancer, a disease that has become the fastest-growing cause of cancer deaths in the United States.
The treatment will cost about $3,500 a month and has the potential to save a family’s life.
According to the Mayo Clinic, about 4,000 Americans die from skin cancer every year.
Many have already started the treatment and are still waiting for results.
Doterra is already used to treat patients who have cancer of the skin and mucous membranes in the eye and mouth, but this treatment will be the first of its kind for patients with cancer of any kind.
Dr. Raffaele Totti, director of the Mayo-affiliated cancer program at New York Presbyterian Hospital, said patients who receive doterraphene will be given a new drug called moclobemide, which is less expensive than a conventional treatment.
Moclobemoide, an oral pill, is used to relieve the pain of chemotherapy and is more effective than surgery.
Patients with a tumor of the mouth or throat who are treated with moclubemide are able to use the drug to reduce the pain for a week or two, according to the American Society of Clinical Oncology.
Totti said the new drug has the promise of saving patients who are already in treatment with the disease.
“I am very optimistic that doterrabotene will be able to slow the growth and reduce the number of new tumors that we have in the coming months,” he said.
As for the people who are taking doterracene, Totti said they are in a very vulnerable position.
“They will need this treatment to stay alive and be able function in society,” he added.
A large number of people have died of cancer since the drug was approved in 2010.
People with advanced or early stage cancers, as well as those with other skin conditions, can expect to have the disease for a longer time.
It’s important to note that this is a new treatment, Totta said.
“It’s very, very experimental and it’s very new,” he told CBS News.
But he stressed that the drug will be safe and effective.
“Doterrachene has been tested in animals and it has been shown to have no side effects.
I am confident that it will work,” he explained.
Totti added that his team hopes to expand the use of doterragisene to other cancers.
“We are looking forward to testing doterraclene for many other cancers and we are very excited about this new treatment,” he concluded.